BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28192473)

  • 1. Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status.
    Suda K; Rozeboom L; Yu H; Ellison K; Rivard CJ; Mitsudomi T; Hirsch FR
    PLoS One; 2017; 12(2):e0172209. PubMed ID: 28192473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromodomain and hedgehog pathway targets in small cell lung cancer.
    Kaur G; Reinhart RA; Monks A; Evans D; Morris J; Polley E; Teicher BA
    Cancer Lett; 2016 Feb; 371(2):225-39. PubMed ID: 26683772
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.
    Hook KE; Garza SJ; Lira ME; Ching KA; Lee NV; Cao J; Yuan J; Ye J; Ozeck M; Shi ST; Zheng X; Rejto PA; Kan JL; Christensen JG; Pavlicek A
    Mol Cancer Ther; 2012 Mar; 11(3):710-9. PubMed ID: 22222631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells.
    Kato F; Fiorentino FP; Alibés A; Perucho M; Sánchez-Céspedes M; Kohno T; Yokota J
    Oncotarget; 2016 Nov; 7(47):77378-77388. PubMed ID: 27764802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion.
    Chalishazar MD; Wait SJ; Huang F; Ireland AS; Mukhopadhyay A; Lee Y; Schuman SS; Guthrie MR; Berrett KC; Vahrenkamp JM; Hu Z; Kudla M; Modzelewska K; Wang G; Ingolia NT; Gertz J; Lum DH; Cosulich SC; Bomalaski JS; DeBerardinis RJ; Oliver TG
    Clin Cancer Res; 2019 Aug; 25(16):5107-5121. PubMed ID: 31164374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
    Helfrich BA; Kim J; Gao D; Chan DC; Zhang Z; Tan AC; Bunn PA
    Mol Cancer Ther; 2016 Oct; 15(10):2314-2322. PubMed ID: 27496133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYCL1 Amplification and Expression of L-Myc and c-Myc in Surgically Resected Small-Cell Lung Carcinoma.
    Qin J; Xie F; Li C; Han N; Lu H
    Pathol Oncol Res; 2021; 27():1609775. PubMed ID: 34257619
    [No Abstract]   [Full Text] [Related]  

  • 8. lncRNAs as Potential Targets in Small Cell Lung Cancer: MYC -dependent Regulation.
    Tokgun O; Tokgun PE; Inci K; Akca H
    Anticancer Agents Med Chem; 2020; 20(17):2074-2081. PubMed ID: 32698750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myc protein expression correlates with MYC amplification in small-cell lung carcinoma.
    Hwang DH; Sun H; Rodig SJ; Hornick JL; Sholl LM
    Histopathology; 2015 Jul; 67(1):81-9. PubMed ID: 25407018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
    Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of arsenic trioxide and chemotherapy in small cell lung cancer.
    Zheng CY; Lam SK; Li YY; Fong BM; Mak JC; Ho JC
    Lung Cancer; 2013 Nov; 82(2):222-30. PubMed ID: 24041618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The spliceosome is a therapeutic vulnerability in MYC-driven cancer.
    Hsu TY; Simon LM; Neill NJ; Marcotte R; Sayad A; Bland CS; Echeverria GV; Sun T; Kurley SJ; Tyagi S; Karlin KL; Dominguez-Vidaña R; Hartman JD; Renwick A; Scorsone K; Bernardi RJ; Skinner SO; Jain A; Orellana M; Lagisetti C; Golding I; Jung SY; Neilson JR; Zhang XH; Cooper TA; Webb TR; Neel BG; Shaw CA; Westbrook TF
    Nature; 2015 Sep; 525(7569):384-8. PubMed ID: 26331541
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [DDP-sensitivity-related genes in 10 lung cancer cell lines].
    Li CH; Cai L; Chen XS; Meng QW; Sui GJ
    Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):418-21. PubMed ID: 19024514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the spliceosome in chronic lymphocytic leukemia with the macrolides FD-895 and pladienolide-B.
    Kashyap MK; Kumar D; Villa R; La Clair JJ; Benner C; Sasik R; Jones H; Ghia EM; Rassenti LZ; Kipps TJ; Burkart MD; Castro JE
    Haematologica; 2015 Jul; 100(7):945-54. PubMed ID: 25862704
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer.
    Huang F; Huffman KE; Wang Z; Wang X; Li K; Cai F; Yang C; Cai L; Shih TS; Zacharias LG; Chung A; Yang Q; Chalishazar MD; Ireland AS; Stewart CA; Cargill K; Girard L; Liu Y; Ni M; Xu J; Wu X; Zhu H; Drapkin B; Byers LA; Oliver TG; Gazdar AF; Minna JD; DeBerardinis RJ
    J Clin Invest; 2021 Jan; 131(1):. PubMed ID: 33079728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Control of the MYC-eIF4E axis plus mTOR inhibitor treatment in small cell lung cancer.
    Matsumoto M; Seike M; Noro R; Soeno C; Sugano T; Takeuchi S; Miyanaga A; Kitamura K; Kubota K; Gemma A
    BMC Cancer; 2015 Apr; 15():241. PubMed ID: 25884680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation.
    Fiorentino FP; Tokgün E; Solé-Sánchez S; Giampaolo S; Tokgün O; Jauset T; Kohno T; Perucho M; Soucek L; Yokota J
    Oncotarget; 2016 May; 7(21):31014-28. PubMed ID: 27105536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy-induced stress response is associated with downregulation of pre-mRNA splicing in cancer cells.
    Anufrieva KS; Shender VО; Arapidi GP; Pavlyukov MS; Shakhparonov MI; Shnaider PV; Butenko IO; Lagarkova MA; Govorun VM
    Genome Med; 2018 Jun; 10(1):49. PubMed ID: 29950180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mistletoe lectin inhibits growth of Myc-amplified small-cell lung cancer.
    Shatat MA; Gauthier B; Yoon S; Yuan E; Yang P; Narla G; Dowlati A; Lee RT
    Cancer Med; 2023 Apr; 12(7):8378-8387. PubMed ID: 36562288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
    Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
    Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.